GSK
GSK
741 hedge funds and large institutions have $9.53B invested in GSK in 2016 Q2 according to their latest regulatory filings, with 69 funds opening new positions, 283 increasing their positions, 259 reducing their positions, and 46 closing their positions.
50% more first-time investments, than exits
New positions opened: 69 | Existing positions closed: 46
41% more call options, than puts
Call options by funds: $179M | Put options by funds: $127M
14% more capital invested
Capital invested by funds: $8.38B → $9.53B (+$1.15B)
2% more funds holding
Funds holding: 726 → 741 (+15)
9% more repeat investments, than reductions
Existing positions increased: 283 | Existing positions reduced: 259
0.23% more ownership
Funds ownership: 3.39% → 3.61% (+0.23%)
9% less funds holding in top 10
Funds holding in top 10: 11 → 10 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$204M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$200M |
| 3 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$158M |
| 4 |
NIMC
NWQ Investment Management Company
Los Angeles,
California
|
+$66.5M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$42.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$155M |
| 2 |
Jane Street
New York
|
-$73.2M |
| 3 |
DM
Deerfield Management
New York
|
-$67.9M |
| 4 |
Millennium Management
New York
|
-$28.1M |
| 5 |
Hotchkis & Wiley Capital Management
Los Angeles,
California
|
-$20.1M |
GSK Hedge Fund Activity: Q2 2016 in Review
741 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in GSK (GSK) for Q2 2016, worth a combined $9.53B — up 14% from $8.38B a quarter earlier.
Buyers outnumbered sellers: 69 funds opened new GSK positions and 46 closed out — a net gain of 23 holders — while 283 added to existing stakes and 259 trimmed.
The largest buyer was Arrowstreet Capital, adding an estimated $204M. The largest seller was JP Morgan Chase, cutting an estimated $155M.
- 741 institutional investors held GSK (GSK) as of Q2 2016, up from 726 in Q1 2016.
- Funds reported $9.53B of GSK stock for Q2 2016, up 14% quarter-over-quarter.
- 69 funds opened new GSK positions in Q2 2016 and 46 closed out, a net change of +23 holders.
- The largest GSK buyer in Q2 2016 was Arrowstreet Capital, an estimated $204M added.
- The largest GSK seller in Q2 2016 was JP Morgan Chase, an estimated $155M sold.
Based on aggregated 13F filings for Q2 2016.